Bio-Path Holdings (BPTH)

$0.82 +0.01 (0.74%)
Market Cap 3.53M
Revenue (ttm) 0.00
Net Income (ttm) -16.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 107,200
Avg Vol 2,574,480
Day's Range N/A - N/A
Shares Out 4.31M
Stochastic %K 25%
Beta 0.08
Analysts Strong Sell
Price Target $12.00

Latest News on BPTH

Bio-Path Holdings Provides 2025 Clinical and Operational Update

Jan 10, 2025, 7:00 AM EST - 8 days ago

Bio-Path Holdings Provides 2025 Clinical and Operational Update

Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

Dec 19, 2024, 7:00 AM EST - 4 weeks ago

Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24

Dec 13, 2024, 4:44 PM EST - 5 weeks ago

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

Dec 11, 2024, 7:00 AM EST - 5 weeks ago

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript

Nov 15, 2024, 9:26 AM EST - 2 months ago

Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript

Bio-Path Holdings Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 7:00 AM EST - 2 months ago

Bio-Path Holdings Reports Third Quarter 2024 Financial Results

Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

Nov 8, 2024, 7:00 AM EST - 2 months ago

Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 10, 2024, 5:24 PM EDT - 3 months ago

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 8, 2024, 8:00 PM EDT - 3 months ago

Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity

Oct 8, 2024, 7:00 AM EDT - 3 months ago

Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24

Sep 4, 2024, 5:48 PM EDT - 4 months ago

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24

Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 7:00 AM EDT - 4 months ago

Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference

Bio-Path Holdings, Inc. (BPTH) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 11:56 AM EDT - 5 months ago

Bio-Path Holdings, Inc. (BPTH) Q2 2024 Earnings Call Transcript

Bio-Path Holdings Reports Second Quarter 2024 Financial Results

Aug 15, 2024, 7:00 AM EDT - 5 months ago

Bio-Path Holdings Reports Second Quarter 2024 Financial Results

Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024

Aug 8, 2024, 7:00 AM EDT - 5 months ago

Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024

Bio-Path Holdings Provides Clinical Update and Expansion Plans

Jul 8, 2024, 7:00 AM EDT - 6 months ago

Bio-Path Holdings Provides Clinical Update and Expansion Plans

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress

Jun 14, 2024, 7:00 AM EDT - 7 months ago

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24

Jun 4, 2024, 4:55 PM EDT - 8 months ago

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 3, 2024, 7:00 AM EDT - 8 months ago

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting

Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

May 24, 2024, 7:00 AM EDT - 8 months ago

Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 5:00 PM EDT - 8 months ago

Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript

May 15, 2024, 11:04 AM EDT - 8 months ago

Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript

Bio-Path Holdings Reports First Quarter 2024 Financial Results

May 15, 2024, 7:00 AM EDT - 8 months ago

Bio-Path Holdings Reports First Quarter 2024 Financial Results

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024

May 8, 2024, 7:00 AM EDT - 9 months ago

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024

Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Apr 19, 2024, 12:14 PM EDT - 9 months ago

Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Apr 18, 2024, 1:57 PM EDT - 9 months ago

Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Apr 18, 2024, 7:00 AM EDT - 9 months ago

Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Bio-Path Holdings Expands Global Patent Portfolio

Apr 15, 2024, 7:00 AM EDT - 9 months ago

Bio-Path Holdings Expands Global Patent Portfolio

Bio-Path Holdings shares sink 6% after deal for at-the-market offering

Apr 4, 2024, 7:14 PM EDT - 10 months ago

Bio-Path Holdings shares sink 6% after deal for at-the-market offering

Bio-Path Holdings Provides 2024 Clinical and Operational Update

Apr 2, 2024, 7:00 AM EDT - 10 months ago

Bio-Path Holdings Provides 2024 Clinical and Operational Update

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23

Mar 27, 2024, 4:43 PM EDT - 10 months ago

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23

Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript

Mar 8, 2024, 10:28 AM EST - 11 months ago

Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript

Bio-Path Holdings Reports Full Year 2023 Financial Results

Mar 8, 2024, 7:00 AM EST - 11 months ago

Bio-Path Holdings Reports Full Year 2023 Financial Results

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024

Mar 1, 2024, 7:00 AM EST - 11 months ago

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

Feb 21, 2024, 7:00 AM EST - 11 months ago

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

Jan 10, 2024, 7:00 AM EST - 1 year ago

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia

Dec 14, 2023, 7:00 AM EST - 1 year ago

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia

Bio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call Transcript

Nov 15, 2023, 5:28 PM EST - 1 year ago

Bio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call Transcript

Bio-Path Holdings Reports Third Quarter 2023 Financial Results

Nov 15, 2023, 7:00 AM EST - 1 year ago

Bio-Path Holdings Reports Third Quarter 2023 Financial Results

Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023

Nov 8, 2023, 7:00 AM EST - 1 year ago

Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023

Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia

Oct 24, 2023, 7:00 AM EDT - 1 year ago

Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia

Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 8, 2023, 4:01 PM EDT - 1 year ago

Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23

Aug 30, 2023, 5:11 PM EDT - 1 year ago

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23

Bio-Path Holdings, Inc. (BPTH) Q2 2023 Earnings Call Transcript

Aug 15, 2023, 1:44 PM EDT - 1 year ago

Bio-Path Holdings, Inc. (BPTH) Q2 2023 Earnings Call Transcript

Bio-Path Holdings Reports Second Quarter 2023 Financial Results

Aug 15, 2023, 7:00 AM EDT - 1 year ago

Bio-Path Holdings Reports Second Quarter 2023 Financial Results

Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023

Aug 8, 2023, 7:00 AM EDT - 1 year ago

Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023

Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering

Aug 3, 2023, 8:22 AM EDT - 1 year ago

Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering

Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

Aug 1, 2023, 7:00 AM EDT - 1 year ago

Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Jul 15, 2023, 1:57 AM EDT - 1 year ago

Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23

Jun 2, 2023, 4:49 PM EDT - 1 year ago

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23